TITAN MEDICAL INC COM NPV (OTCMKTS:TITXF) Is Running, What's Next?

Back on September 25, 2017, we published this piece on TITAN MEDICAL INC COM NPV (OTCMKTS:TITXF).As part of our coverage, we noted that the company was heading into what could be a pivotal phase and that we would likely see some appreciation in its market capitalization heading into the close of 2017 and beyond.At the time, Titan traded for a little over $0.20 a share.Fast forward to this week and the company now goes for $0.42 – a 110% appreciation in a matter of weeks.That's a nice return for any of our readers that took a position on the back of our bull thesis but, with the run in the bag, we've got to ask the question – what's next?Before we try and answer it, let's quickly introduce the stock for anyone reading that's not come across Titan before. TITXF Daily ChartThe company is a biotechnology play that's working to commercialize what it calls its SPORT Surgical System.The system is a technology platform that allows for robotic surgical procedure to be carried out in a minimally invasive manner. A surgeon stands behind a screen, on which an image of the patient that's being operated on is displayed. The surgeon uses the machine to control a surgical robot type technology, operating remotely through a small incision in the patient's skin.These sorts of systems have long been regarded as the surgical approach of the future – practically every time we see future surgery portrayed in science fiction it's a robot that's carrying it out, not a human surgeon – but to date, only one system has achieved any degree of mainstream success, a system called Da Vinci.With SPORT, Titan is trying to challenge the dominance of the Da Vinci system in the US and internationally and right now it's in a position where it's all about pushing the product into various healthcare facilities around the world.The sales cycle on this sort of technology is pretty long, meaning the going is relatively slow, but Titan is now at a point where it's seeing installations take place and, as more of these installations come in, the company is going to be able to increase its topline and – by proxy – become more attractive to potential shareholders looking to gain exposure to this nascent subsector of healthcare.The latest announcement outlined the fact that Titan has installed a SPORT system at Columbia's simulation training facility in New York City. This is the second U.S. installation of the technology for preclinical feasibility and validation studies and the first at an academic medical center. It's also the second of three planned installations in this sort of setting.So what are we looking for going forward and can we answer the initial question – is there any run room left?Well, we really want to see Titan gather some strong evidence that its system can outcompete the above mentioned Da Vinci technology. It's a brand new system (whereas the Da Vinci is nearly 20 years old) so there's definitely going to be a technological edge, but in this space, it's also important that the system can be used easily by surgeons. In other words, it can be as technologically advanced as it wants but if it doesn’t feel right for a surgeon it's not going to gain any traction.Going forward then, we're looking for some feedback from physicians at the new installation sites to validate the product's usability.If we get what we're looking for, there's no reason that Titan can't continue to run into the end of this year and beyond.You can find our previous coverage of this stock here. We will be updating our subscribers as soon as we know more. For the latest updates on TITXF, sign up below!Image courtesy of Army Medicine via FlickrDisclosure: We have no position in TITXF and have not been compensated for this article.